The global spinal muscular atrophy treatment market size was valued at USD 5.09 billion in 2025 and is projected to grow from USD 5.99 billion in 2026 to USD 22.17 billion by 2034, registering a CAGR of 17.76% during the forecast period from 2026 to 2034. North America dominated the spinal muscular atrophy treatment market with a market share of 42.5% in 2025.
Spinal Muscular Atrophy (SMA) is a neuromuscular disorder possessing an autosomal recessive hereditary genetic profile. SMA is one of the fatal diseases with an incidence rate of 1 per 6,000 births to 1 per 10,000 births. The heterozygote carrier frequency of SMA is about 1 in every 40 to 60 people across the globe. It severely affects the motor neurons in the brain and spinal cord due to the homozygous mutation of the survival motor neuron gene 1 (SMN1). These motor neurons bring about the transfer of chemical and electrical charge to and fro from the voluntary muscles, present all over the body. Thereby, the affected motor neurons in the brain and spinal cord cause difficulty in performing several physical activities, including swallowing, crawling, and walking. SMA is a difficult disorder to diagnose, depending upon both histological and electrophysiological evidence of muscle denervation with uncertain results of treatment.
Download a Free Sample To learn more about this report,
Growing Advancements in Gene Therapy and Early Diagnosis
The spinal muscular atrophy treatment market trends are increasingly driven by rapid progress in gene therapy and newborn screening programs. Early diagnosis allows infants with spinal muscular atrophy (SMA) to receive treatment before significant motor neuron damage occurs, leading to improved long-term outcomes. According to the U.S. Centers for Disease Control and Prevention (CDC), SMA is one of the leading genetic causes of infant mortality, prompting many countries to expand newborn screening initiatives. At the same time, continued innovation in gene replacement therapies and disease-modifying treatments is improving survival rates and quality of life for patients.
Rising Investments in RNA-Based Therapies and Global Access Programs
The spinal muscular atrophy treatment market is witnessing steady growth due to increasing investments in RNA-targeted therapies, expanded reimbursement policies, and broader patient access initiatives. Pharmaceutical companies are collaborating with healthcare providers and governments to improve access to life-changing therapies, particularly in regions where rare disease treatment availability has been limited. Growing awareness among clinicians and patient advocacy organizations is also contributing to earlier diagnosis and improved treatment uptake.
Advancements in Gene Therapy and Early Disease Diagnosis
The spinal muscular atrophy treatment market growth is primarily driven by significant advancements in gene therapy, RNA-targeted therapies, and newborn screening programs. Early diagnosis enables timely treatment before irreversible motor neuron damage occurs, improving survival rates and motor function in affected patients. Increasing awareness among healthcare professionals and caregivers, along with expanding access to genetic testing, has accelerated the adoption of innovative SMA therapies. The spinal muscular atrophy treatment market growth is also supported by rising investments in rare disease research, improved reimbursement programs in several countries, and continuous development of next-generation therapies that offer better long-term clinical outcomes.
High Treatment Costs and Limited Patient Access
The spinal muscular atrophy treatment market faces significant restraints due to the exceptionally high cost of gene therapies and long-term disease-modifying treatments. Limited reimbursement coverage, complex pricing negotiations, and disparities in healthcare infrastructure restrict access to these therapies, particularly in low- and middle-income countries. The spinal muscular atrophy treatment market analysis also indicates that specialized treatment centers, genetic testing facilities, and multidisciplinary care teams are not widely available in many regions. In addition, lengthy regulatory approval processes and manufacturing complexities contribute to high development and commercialization costs.
Expansion of Personalized Medicine and Next-Generation Therapies
The growing focus on personalized medicine is creating substantial opportunities for the spinal muscular atrophy treatment market. Pharmaceutical companies are developing improved gene replacement therapies, RNA-modifying drugs, and combination treatment strategies aimed at enhancing long-term efficacy and patient outcomes. The spinal muscular atrophy treatment market analysis highlights increasing investments in biomarker research, advanced genetic diagnostics, and innovative drug delivery technologies that support earlier intervention and individualized treatment plans. Expanding newborn screening programs and increasing healthcare investment in rare diseases are expected to create significant growth opportunities for market participants.
Ensuring Long-Term Treatment Outcomes and Global Accessibility
One of the major challenges facing the spinal muscular atrophy treatment market is ensuring durable clinical benefits while making advanced therapies accessible to a broader patient population. Long-term monitoring is essential to evaluate treatment effectiveness, safety, and disease progression, requiring ongoing medical support and specialized care. The spinal muscular atrophy treatment market growth is also affected by manufacturing capacity limitations, evolving regulatory requirements, and unequal access to genetic testing and treatment facilities across regions. Balancing innovation, affordability, and equitable patient access remains a critical challenge for companies operating in the global spinal muscular atrophy treatment market.
Request Customizationto receive a tailored report.
Severe (Type I, Severe SMA or Werdnig-Hoffmann Disease) Dominated the Market with 46.8% Share in 2025
The severe (Type I, severe SMA or Werdnig-Hoffmann disease) segment accounted for the largest share of the global spinal muscular atrophy treatment market at 46.8% in 2025, driven by early disease onset, high treatment urgency, increasing newborn screening programs, and the availability of advanced disease-modifying therapies.
The intermediate (Type II or chronic SMA) segment continues to witness significant demand as patients require long-term disease management and supportive care. Mild (Type III, juvenile SMA or Kugelberg-Welander disease) is experiencing steady adoption of therapeutic interventions due to improved diagnosis and better treatment accessibility, while Type IV (adult SMA) remains an emerging segment supported by increasing awareness and advancements in adult neurological care.
Drugs are Projected to Register the Fastest Growth at a CAGR of 13.7%
The drugs segment is expected to expand at the highest CAGR of 13.7% during 2026–2034, driven by continuous advancements in disease-modifying therapies, expanding regulatory approvals, and increasing access to innovative pharmaceutical treatments for spinal muscular atrophy.
Gene therapy continues to play a transformative role by offering long-term therapeutic benefits through genetic correction. Medication and physical therapy remain essential components of comprehensive disease management, helping improve patient mobility and quality of life, while surgery is utilized in selected cases to address musculoskeletal complications. Other supportive treatment approaches continue to complement standard therapeutic strategies.
Intrathecal Dominated the Market with 42.9% Share in 2025
The intrathecal segment accounted for the largest share of the global spinal muscular atrophy treatment market at 42.9% in 2025, driven by the widespread use of intrathecal therapies that deliver medication directly into the cerebrospinal fluid for improved therapeutic effectiveness.
Oral administration is witnessing increasing adoption due to improved patient convenience and the growing availability of orally administered therapies. Parenteral administration also continues to gain traction with the introduction of advanced biologics and innovative treatment options for spinal muscular atrophy.
Abeparvovec is Projected to Register the Fastest Growth at a CAGR of 16.4%
The abeparvovec segment is anticipated to witness the fastest growth, registering a CAGR of 16.4% during 2026–2034, fueled by increasing adoption of gene replacement therapy, favorable clinical outcomes, and expanding treatment availability.
Nusinersen remains one of the most widely prescribed therapies due to its established clinical efficacy and broad adoption across healthcare settings. Onasemnogene continues to experience strong demand as healthcare providers increasingly adopt gene therapies for long-term disease management, while other emerging therapies are expanding treatment options through ongoing clinical research and innovation.
Intrathecal Dominated the Market with 44.3% Share in 2025
The intrathecal administration segment accounted for the largest share of the global spinal muscular atrophy treatment market at 44.3% in 2025, supported by the extensive use of intrathecal delivery for approved SMA therapies and its proven effectiveness in treating neurological disorders.
Subcutaneous administration is expected to gain momentum with the development of more patient-friendly therapies that simplify treatment delivery. Intraspinal administration continues to be utilized in specialized clinical settings, while other administration methods are being explored to improve treatment accessibility and patient outcomes.
Online Pharmacy is Projected to Register the Fastest Growth at a CAGR of 16.2%
The online pharmacy segment is expected to expand at the highest CAGR of 16.2% during 2026–2034, driven by increasing digital healthcare adoption, convenient medicine delivery services, and improved access to specialty therapies.
Hospital pharmacies continue to serve as the primary distribution channel owing to the specialized handling and administration requirements of SMA therapies. Retail pharmacies also play an important role by improving patient access to prescribed medications and supporting ongoing disease management.
Speak to an Analystto discuss market opportunities.
North America dominated the spinal muscular atrophy treatment market with a 42.5% share, valued at USD 2.16 billion in 2025. The region's leadership is driven by the high prevalence of rare disease diagnosis, strong adoption of advanced gene and disease-modifying therapies, favorable reimbursement policies, and substantial investments in rare disease research. Well-established healthcare infrastructure and increasing newborn screening programmes continue to support regional market growth.
The United States accounted for the largest share of the North American market in 2025. Growth is driven by increasing adoption of innovative gene therapies, strong government support for rare disease treatment, expanding newborn screening programmes, and the presence of leading biotechnology and pharmaceutical companies. Favorable reimbursement policies and ongoing clinical research further strengthen the country's market position.
Canada is witnessing steady market growth due to expanding access to advanced SMA therapies, increasing investments in rare disease research, growing awareness of early diagnosis, and supportive healthcare reimbursement programmes. Rising adoption of genetic testing is further contributing to market expansion.
Europe accounted for 29.4% of the global spinal muscular atrophy treatment market, reaching USD 1.5 billion in 2025, and is projected to register the fastest CAGR of 15.6% during the forecast period. Market growth is supported by expanding newborn screening initiatives, increasing access to innovative therapies, rising investments in rare disease research, and favorable government policies for orphan drugs. Continuous advancements in genetic medicine continue to drive regional demand.
The United Kingdom is witnessing steady market growth owing to increasing adoption of advanced SMA therapies, expanding genetic screening programmes, rising investments in rare disease research, and strong support from the national healthcare system for innovative treatments.
Germany represents one of the largest markets in Europe, driven by advanced healthcare infrastructure, increasing availability of gene therapies, strong clinical research activities, and growing government support for rare disease management.
Asia Pacific accounted for 20.1% of the global spinal muscular atrophy treatment market, valued at USD 1.02 billion in 2025. The market is expanding due to improving healthcare infrastructure, increasing awareness of genetic disorders, rising adoption of newborn screening programmes, and growing investments in advanced biotechnology. Expanding access to innovative therapies is supporting regional market growth.
Japan is witnessing steady market growth due to its advanced healthcare system, increasing adoption of innovative gene therapies, expanding rare disease research, and strong government support for precision medicine and early diagnosis programmes.
China accounted for the largest share of the Asia Pacific market in 2025. Growth is supported by increasing healthcare expenditure, expanding access to rare disease treatments, growing investments in biotechnology, and rising awareness of early genetic diagnosis and screening.
The Middle East & Africa represented 3.4% of the global spinal muscular atrophy treatment market, totaling USD 0.17 billion in 2025. Rising investments in specialized healthcare services, improving access to rare disease diagnosis, expanding genetic testing capabilities, and increasing government healthcare spending are supporting regional market growth.
The UAE is a key market in the Middle East, driven by increasing investments in advanced healthcare infrastructure, expanding access to innovative genetic therapies, growing awareness of rare diseases, and strong government initiatives to improve specialized healthcare services.
Africa is witnessing gradual market growth, supported by improving healthcare infrastructure, increasing awareness of rare genetic disorders, expanding access to diagnostic services, and growing collaborations with international healthcare organizations. Countries such as South Africa, Egypt, and Kenya are creating long-term growth opportunities for market participants.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com